National Comprehensive Cancer Network

About NCCN

NCCN Updates: Guidelines, Drugs & Biologics, Order Templates

NCCN Clinical Practice Guidelines in Oncology™ for Prostate Cancer Early Detection Updated

The NCCN Clinical Practice Guidelines in Oncology™ for Prostate Cancer Early Detection have been updated to reflect new evidence from studies published in 2009. Level 1 evidence for PSA screening is now available through a European study released in 2009. The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in the early 1990s to evaluate the effect of prostate-specific antigen (PSA) testing on death rates from prostate cancer. The researchers concluded that PSA-based screening reduced the rate of death from prostate cancer by 20%. However, they also concluded that this was associated with a high risk of over-diagnosis. Statistically, 1,410 men would need to be screened and 48 men would need to be treated to prevent one death from prostate cancer. Click here for the complete Guidelines for Prostate Cancer Early Detection.

For the complete updated version of the NCCN Clinical Practice Guidelines in Oncology™, please visit NCCN.org.